Condition: Metastatic Castration-resistant Prostate Cancer · Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Chao Family Comprehensive Cancer Centre | Orange, California, United States | Active Not Recruiting |
| Biogenix Molecular LLC | Miami, Florida, United States | Active Not Recruiting |
| United Theranostics | Glen Burnie, Maryland, United States | Active Not Recruiting |
| XCancer Omaha | Omaha, Nebraska, United States | Active Not Recruiting |
| Columbia University Herbert Irving Comphrensive Cancer Center | New York, New York, United States | Recruiting |
| University Hospital | Cleveland, Ohio, United States | Active Not Recruiting |
| OHSU Knight Cancer Center | Portland, Oregon, United States | Active Not Recruiting |
| Intermountain Health | Murray, Utah, United States | Active Not Recruiting |
| Intermountain Health | Salt Lake City, Utah, United States | Active Not Recruiting |
| Westmead Hospital | Sydney, New South Wales, Australia | Recruiting |
| Nepean Hospital | Sydney, New South Wales, Australia | Recruiting |
| Wollongong Hospital | Wollongong, New South Wales, Australia | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06520345